< Back to Thought Leadership

340B Program HRSA Response to Pharmaceutical Manufacturers

After months of pharmaceutical manufacturers placing restrictions on the 340B Program to both contract pharmacies and covered entities, HRSA sent letters to six pharmaceutical manufacturers stating they violated the 340B Statute. The HRSA Acting Administrator declared these pharmaceutical manufacturers violated the 340B statue by placing restrictions on the 340B Program pricing at both contract pharmacy locations and covered entities.

Six Pharmaceutical Manufacturers Violated the 340B Statute

In HRSA’s response, they detail some of the ways manufacturers were in violation of the 340B Statute:

  • Limiting covered entity’s access to the drugs they were able to purchase through the 340B Program
  • Stopped providing the 340B ceiling price
  • Dispensing drugs through contract pharmacies
  • Required specific data submissions to limit sales

HRSA instructed the pharmaceutical manufacturers remove the restrictions and begin offering the covered outpatient drugs at the 340B Program ceiling price at covered entities contract pharmacies. The pharmaceutical manufacturers have until June 1, 2021 to comply.

The full release from HRSA can be found on the OPA webpage.

Have Questions about What this Means for Your Organization? 

Our team will continue to provide updates as more information is released about the 340B Program and HRSA’s response. We recommend that you begin working with your TPA vendor to begin to assess what savings are owed to your location from the months of restrictions. If you would like one of our 340B Program experts to reach out to you, please fill out the form below and they will contact you within 24 hours.


How to Manage Clinical Validation Denials

In the past several years, hospitals have continued to feel the impact on revenue from Clinical Validation Denials (CVD). The need for a robust CDI team to capture support for clinical indicators while the patient is still in house is more imperative than ever. The other overwhelming piece for revenue cycle teams to manage is […]

Learn More

Margin Improvement: Optimizing Financial Performance

Ensuring the long-term financial viability of a health system requires constant attention to the operating statement. This involves assessing the current state of your healthcare organization and critically comparing the current condition to industry and/or internal benchmark standards. Ultimately, this assessment assists management implement an ongoing margin improvement process to increase the likelihood of achieving […]

Learn More

Blue Named One of Kentucky’s Best Places to Work

CARMEL, Ind. (May 3, 2023) – Blue & Co., LLC is honored to be named among the Best Places to Work in Kentucky by the Kentucky Chamber of Commerce, the Kentucky Society for Human Resource Management (KYSHRM) and ClearPath Mutual Insurance Company. This is the 12th year Blue & Co. has made the list as […]

Learn More